Opdivo’s lung cancer latest: one fail, one shrug - Vantage

Opdivo’s lung cancer latest: one fail, one shrug  Vantage

Bristol-Myers Squibb's byzantine Checkmate-227 study yields one flop and one technical success that, in reality, counts for nothing. Trees in the shape of a pair ...